Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 27 recruiting now early-phase tilt

Gynecologic Cancer: early-phase trial registry

27 of 56 indexed Gynecologic Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #252 of 28,707 conditions by registered trial count.

56 US clinical trials · 27 currently recruiting · #252 of 28,707 conditions by registered trial count

Gynecologic Cancer: 56 US clinical trials tracked, 27 recruiting.

Gynecologic Cancer is the subject of 56 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 6 of these trials.

Enrollment posture brief

Registry condition gynecologic-cancer

OPEN 27 | RECR 48% | LATE 2 | EARLY 16 | RANK #252 | SPON 6

Nearest open-share peer: Advanced Solid Tumors (48% recruiting · 145 trials)

Sleep Disturbance56.1%Gynecologic Cancer (this)48%Trauma43.9%Soft Tissue Sarcoma39.3%Ocular Hypertension21.1%
Open-enrollment share among volume-matched conditions near Gynecologic Cancer

Gynecologic Cancer lists 27 open slots (48% of 56 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Gynecologic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Gynecologic Cancer is recruiting above its size-band peers.

    27 of 56 indexed trials (48.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Gynecologic Cancer trials is spread across many organizations.

    Dana-Farber Cancer Institute accounts for 6 of 56 trials (10.7%). 37 distinct sponsors appear on at least one study for this condition label.

  3. Most Gynecologic Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 56 trials that report a genuine target (sentinel values excluded). 34 of those (60.7%) plan for fewer than 100 participants.

  4. Gynecologic Cancer research is mostly interventional.

    46 interventional and 10 observational studies make up this index (82.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 210Phase 32

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 10
Phase 3 2

Named interventions

Most-linked intervention names on Gynecologic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
Riluzole Drug
2 trials
Radiation therapy Radiation
2 trials
Sexual and Menopausal Health Resources Only Behavioral
1 trials
[18F]Fluorothymidine (FLT) PET/CT Imaging Radiation
1 trials
Subcutaneous enoxaparin Drug
1 trials
Oral apixaban Drug
1 trials
prasterone Drug
1 trials

US sites by state

Facility locations filed on Gynecologic Cancer trials. A trial with sites in several states counts in each.

California 9 trials
New York 8 trials
Massachusetts 8 trials
Texas 5 trials
New Jersey 5 trials
Utah 4 trials
Virginia 3 trials
Pennsylvania 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Gynecologic Cancer page

56 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gynecologic Cancer condition card totals 56 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.